Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913279
rs121913279
PIK3CA
G 0.710 CausalMutation CLINVAR PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. 22271473

2012
dbSNP: rs2363956
rs2363956
ANKLE1
0.710 GeneticVariation BEFREE To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13. 22235027

2012
dbSNP: rs2665390
rs2665390
TIPARP ; LOC107986148
0.710 GeneticVariation BEFREE To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13. 22235027

2012
dbSNP: rs41293459
rs41293459
BRCA1
0.710 GeneticVariation BEFREE BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. 22889855

2012
dbSNP: rs121913343
rs121913343
TP53
0.710 GeneticVariation BEFREE We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases. 21535297

2011
dbSNP: rs121913529
rs121913529
KRAS
G 0.710 CausalMutation CLINVAR Epidermal growth factor receptor blockers for the treatment of ovarian cancer. 21975775

2011
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR Epidermal growth factor receptor blockers for the treatment of ovarian cancer. 21975775

2011
dbSNP: rs121913529
rs121913529
KRAS
0.710 GeneticVariation BEFREE In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. 21632463

2011
dbSNP: rs121913529
rs121913529
KRAS
A 0.710 CausalMutation CLINVAR Epidermal growth factor receptor blockers for the treatment of ovarian cancer. 21975775

2011
dbSNP: rs10088218
rs10088218
LINC00824
G 0.710 GeneticVariation GWASCAT A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. 20852632

2010
dbSNP: rs2363956
rs2363956
ANKLE1
T 0.710 GeneticVariation GWASCAT Common variants at 19p13 are associated with susceptibility to ovarian cancer. 20852633

2010
dbSNP: rs2665390
rs2665390
TIPARP ; LOC107986148
C 0.710 GeneticVariation GWASCAT A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. 20852632

2010
dbSNP: rs8170
rs8170
BABAM1 ; USHBP1
0.710 GeneticVariation BEFREE Expression analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1-interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development. 20852633

2010
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. 19047918

2009
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. 19358724

2009
dbSNP: rs121913529
rs121913529
KRAS
G 0.710 CausalMutation CLINVAR KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 19018267

2008
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 19018267

2008
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. 17910045

2008
dbSNP: rs121913529
rs121913529
KRAS
A 0.710 CausalMutation CLINVAR KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 19018267

2008
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 17332249

2007
dbSNP: rs104886003
rs104886003
PIK3CA
A 0.710 CausalMutation CLINVAR Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. 15647370

2005
dbSNP: rs121913279
rs121913279
PIK3CA
T 0.710 CausalMutation CLINVAR Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. 15647370

2005
dbSNP: rs121913279
rs121913279
PIK3CA
G 0.710 CausalMutation CLINVAR Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. 15647370

2005
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. 15696205

2005
dbSNP: rs121913529
rs121913529
KRAS
T 0.710 CausalMutation CLINVAR Somatic PTPN11 mutations in childhood acute myeloid leukaemia. 15842656

2005